Cargando…
Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies
INTRODUCTION: The purpose of this retrospective study was to determine the clinical utility of serum HER2/neu in monitoring metastatic breast cancer patients undergoing trastuzumab-based therapy and to compare these results with those obtained using cancer antigen (CA) 15-3. We also sought to determ...
Autores principales: | Esteva, Francisco J, Cheli, Carol D, Fritsche, Herbert, Fornier, Monica, Slamon, Dennis, Thiel, Robert P, Luftner, Diana, Ghani, Farooq |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1175054/ https://www.ncbi.nlm.nih.gov/pubmed/15987448 http://dx.doi.org/10.1186/bcr1020 |
Ejemplares similares
-
Trastuzumab for Her2/neu-positive metastatic salivary gland carcinoma: Case report and review of the literature
por: Firwana, Belal, et al.
Publicado: (2012) -
Pro1170 Ala polymorphism in HER2-neu is associated with risk of trastuzumab cardiotoxicity
por: Stanton, Sasha E, et al.
Publicado: (2015) -
Use of the anti HER-2/neu antibody Herceptin in the treatment of human breast cancer: biological rationale and clinical results
por: Slamon, DJ
Publicado: (2000) -
Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
por: de Oliveira Taveira, Mateus, et al.
Publicado: (2017) -
HER2 therapy: Molecular mechanisms of trastuzumab resistance
por: Nahta, Rita, et al.
Publicado: (2006)